J&J touts latest immune response data for 'mosaic' HIV vaccine program

Johnson & Johnson has already advanced a “mosaic” HIV vaccine candidate into efficacy testing in five southern African countries, but this week the company unveiled initial results from an early-stage study comparing tetravalent and trivalent candidates in its program.